Alert detail
FDA Approval: NAVITRUX (FOSAPREPITANT) — Type 5 - New Formulation or New Manufacturer
Policy ID: FDA-NDA220436Specialty: OncologyAdded: 6/30/2026Effective: 2026-06-24billing update
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.